Treatment of High-Grade Glioma Patients With the Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Antibody H-R3: Report From a Phase I/Ii Trial

Cancer Biology and Therapy - United States
doi 10.4161/cbt.5.4.2522
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Phase II Trial of Anti-Epidermal Growth Factor Receptor Radioimmunotherapy in the Treatment of Anaplastic Astrocytoma

Journal of Radiation Oncology
OncologyRadiologyNuclear MedicineImaging
2012English

Phase I Study of Tomuzotuximab, a Glycoengineered Therapeutic Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Carcinomas

ESMO Open
Cancer ResearchOncology
2018English

BRAF; Epidermal Growth Factor Receptor (EGFR)

Science-Business eXchange
2012English

A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors

Investigational New Drugs
OncologyPharmacology
2014English

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Epidermal Growth Factor Receptor in Human Glioma

Journal of Neurosurgery
SurgeryNeurology
1989English

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

Structural Characterization of a Potent Humanized Anti-Cd38 Antibody in Phase I

Acta Crystallographica Section A: Foundations and Advances
Materials ScienceCondensed Matter PhysicsTheoretical ChemistryBiochemistryStructural BiologyInorganic ChemistryPhysical
2014English

Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report From Iran

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy